Inclusion Criteria:

          -  Subjects may be male or female, and must be aged =/>18 years on the date of signing
             the informed consent form.

          -  Subjects must have histologically confirmed, unresectable, locally advanced or
             metastatic pleural or peritoneal predominantly (>50% of tumor component) epithelial
             mesothelioma or nonsquamous non-small-cell lung cancer (NSCLC). Both
             chemotherapy-naive and previously treated subjects will be eligible; however, newly
             diagnosed NSCLC subjects eligible for FDA-approved therapies should have received the
             same before enrollment (e.g. subjects with epidermal growth factor receptor
             [EGFR]-mutated and anaplastic lymphoma kinase [ALK]-translocated NSCLC should have
             received FDA-approved targeted therapies).

          -  Subjects must have at least 1 measurable or evaluable tumor lesion according to RECIST
             1.1 (for nonsquamous NSCLC) or mRECIST (for epithelial pleural mesothelioma). Subjects
             with resected primary tumors who have documented metastases are eligible.

          -  Subjects must have a life expectancy of at least 12 weeks.

          -  Subjects must have ECOG (Eastern Cooperative Oncology Group performance Status of 0 or
             1

          -  Subjects must have adequate bone marrow, liver, kidney, and coagulation functions.

        Exclusion Criteria:

          -  Subjects who have a previous or concurrent cancer that is distinct in primary site or
             histology from the cancer being evaluated in this study, or any previous cancer
             curatively treated >3 years before the start of study Treatment.

          -  Subjects who have a history or current evidence of bleeding disorder, i.e. any
             hemorrhage / bleeding event of CTCAE (Common Terminology Criteria for Adverse Events)
             Grade ≥2 within 4 weeks before the start of study Treatment.

          -  Subjects who have new or progressive brain or meningeal or spinal metastases.

          -  Subjects who have a history or current evidence of uncontrolled cardiovascular disease
             i.e. NYHA (New York Heart Association) Class III or IV.

          -  Subjects who have a history or current evidence of uncontrolled hypertension defined
             as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at
             screening despite optimal medical management.

          -  Subjects who have a history or current evidence of malignant biliary obstruction
             requiring biliary stent.

          -  Subjects who have had solid organ or bone marrow Transplantation.

          -  Subjects who have a history of hypersensitivity to any of the study drugs or their
             excipients, or a history of severe hypersensitivity to any other Antigen.

          -  Subjects who have a history of human immunodeficiency virus (HIV) infection or
             subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV)
             infection requiring treatment.

          -  Subjects who have an active clinically serious infection of CTCAE Grade ≥2 or
             non-healing wound unrelated to the primary Tumor.

          -  Subjects who have received systemic cancer therapy, radiotherapy, investigational drug
             treatment outside of this study within 4 weeks before the start of study treatment,
             granulocyte colony stimulating factors, (G-CSF) or granulocyte macrophage-stimulating
             factors (GM-CSF), erythropoietin-stimulating agents within 3 weeks before the start of
             general screening, drugs with known renal toxicity and strong cytochrome P450 3A4
             (CYP3A4) inhibitors or strong CYP3A4 inducers within 2 weeks before the treatment.

          -  Subjects who have started oral or parenteral anticoagulation therapy within 2 weeks
             before the start of anetumab ravtansine until end of treatment visit.